Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Multiple ascending dose study of BMS-986326 in cutaneous or systemic lupus
NL-OMON61014Phase 1Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Jun 2024
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1 trial of BMS-986326 in discoid lupus erythematosus (DLE), subacute cutaneous lupus erythematosus (SCLE) and systemic lupus erythematosus (SLE), sponsored by Bristol Myers Squibb. Primary endpoint: Primary endpoint(s). Started Jun 2024; status: completed.
02
Drugs
BMS-986326
03
Conditions
discoid lupus erythematosus (DLE)subacute cutaneous lupus erythematosus (SCLE)systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on NL-OMON61014.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON61014.